Should you buy Omnicell (OMCL)?
Updated
Omnicell offers a compelling combination of 33% analyst upside, a PEG of 0.05, and free cash flow conversion of 551% relative to net income alongside a Piotroski F-Score of 8/9, but momentum has slipped below the minimum threshold and the stock trades well above the options market's max pain level of $35.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Omnicell converts free cash flow at 551% of net income and holds a Piotroski F-Score of 8/9, reflecting high-quality recurring revenue from its pharmacy automation and services business where customers pay upfront or in advance, creating cash flows that substantially exceed reported accounting earnings. Quality breakdown | Free cash flow conversion remains above 300% of net income over the next 4 reported quarters, confirming the structural quality of the revenue model. | →Stable |
| CounterA very high free cash flow to net income ratio in a healthcare IT company can reflect large stock-based compensation charges that reduce GAAP earnings without reducing cash — a compensation cost that dilutes shareholder value even if it does not consume cash. | ||
With a PEG ratio of 0.05 and analysts projecting 53% upside to consensus targets at approximately $53, Omnicell appears priced at a significant discount to its growth trajectory, suggesting the market has not yet fully valued the healthcare automation opportunity. Valuation breakdown | Stock price rises above $50 within 12 months as analyst targets are progressively achieved through earnings delivery. | →Stable |
| CounterA PEG of 0.05 is an extreme reading that likely reflects earnings at a trough with high projected recovery rather than genuine undervaluation, and the current price of $40 near the 52-week mid-range suggests the market is appropriately skeptical of the recovery timeline. | ||
Omnicell beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 38.5%, including beats of 66% and 67% in two recent quarters, indicating that the healthcare automation business is generating profits well above analyst models. Earnings | Earnings beat streak extends to at least 3 of the next 4 quarters as pharmacy automation adoption continues in hospital systems. | →Stable |
| CounterThe one miss was -19.4% and the large positive surprises may reflect lumpy revenue recognition from multi-year automation contracts rather than sustainable sequential improvement, creating uncertainty about the reliability of the beat pattern. | ||
Omnicell converts free cash flow at 551% of net income and holds a Piotroski F-Score of 8/9, reflecting high-quality recurring revenue from its pharmacy automation and services business where customers pay upfront or in advance, creating cash flows that substantially exceed reported accounting earnings.
→Stable- Expectation
- Free cash flow conversion remains above 300% of net income over the next 4 reported quarters, confirming the structural quality of the revenue model.
CounterA very high free cash flow to net income ratio in a healthcare IT company can reflect large stock-based compensation charges that reduce GAAP earnings without reducing cash — a compensation cost that dilutes shareholder value even if it does not consume cash.
With a PEG ratio of 0.05 and analysts projecting 53% upside to consensus targets at approximately $53, Omnicell appears priced at a significant discount to its growth trajectory, suggesting the market has not yet fully valued the healthcare automation opportunity.
→Stable- Expectation
- Stock price rises above $50 within 12 months as analyst targets are progressively achieved through earnings delivery.
CounterA PEG of 0.05 is an extreme reading that likely reflects earnings at a trough with high projected recovery rather than genuine undervaluation, and the current price of $40 near the 52-week mid-range suggests the market is appropriately skeptical of the recovery timeline.
Omnicell beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 38.5%, including beats of 66% and 67% in two recent quarters, indicating that the healthcare automation business is generating profits well above analyst models.
→Stable- Expectation
- Earnings beat streak extends to at least 3 of the next 4 quarters as pharmacy automation adoption continues in hospital systems.
CounterThe one miss was -19.4% and the large positive surprises may reflect lumpy revenue recognition from multi-year automation contracts rather than sustainable sequential improvement, creating uncertainty about the reliability of the beat pattern.
▸ Show 1 more pillar▾ Show fewer
Momentum has fallen below the minimum required threshold of 4.5 at a score of 4.1, and the current price of $40 is significantly above the options market's max pain level of $35, creating dual technical and options-market headwinds that suggest the near-term path of least resistance may be sideways to lower.
→Stable- Expectation
- Momentum score recovers above 5.0 within 3 months as price consolidates above the $35 max pain level and volume patterns normalize.
CounterMomentum weakness and options market max pain misalignment are short-term technical factors that tend to self-correct, especially when the underlying business is generating strong earnings beats and analysts maintain high price targets.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Omnicell converts free cash flow at 551% of net income and holds a Piotroski F-Score of 8/9, reflecting high-quality recurring revenue from its pharmacy automation and services business where customers pay upfront or in advance, creating cash flows that substantially exceed reported accounting earnings.
Trip ifFree cash flow conversion falls below 200% of net income for 2 consecutive quarters, indicating the structural quality advantage is deteriorating.
- P2With a PEG ratio of 0.05 and analysts projecting 53% upside to consensus targets at approximately $53, Omnicell appears priced at a significant discount to its growth trajectory, suggesting the market has not yet fully valued the healthcare automation opportunity.
Trip ifAnalyst consensus price target falls below $45, reducing projected upside to less than 13% from current price levels.
- P3Omnicell beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 38.5%, including beats of 66% and 67% in two recent quarters, indicating that the healthcare automation business is generating profits well above analyst models.
Trip ifEPS surprise falls below -15% in at least 2 of the next 3 quarters, indicating the beat pattern has reversed.
- P4Momentum has fallen below the minimum required threshold of 4.5 at a score of 4.1, and the current price of $40 is significantly above the options market's max pain level of $35, creating dual technical and options-market headwinds that suggest the near-term path of least resistance may be sideways to lower.
Trip ifStock price drops below $35 (the current options max pain level) and stays below it for more than 20 trading days, confirming options-market headwinds are exerting sustained pressure.
How the engine reached this verdict
TrendMatrix's engine output for Omnicell, Inc. (OMCL) is SELL_IF_HOLDING with medium conviction, score 5.3/10 at $40.44. The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 3.25 is supplementary context, not the trigger.
The dominant failed gate is momentum at 3.0 vs threshold 4.5. SELL flips back toward HOLD if momentum recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is ASYMMETRY:3.2>=1.5.
On the bull side: Strong earnings beat streak (3/4); Analyst upside: 32%. On the bear side: Negative momentum. Active engine warnings: V9 Gate Failed: MOMENTUM:3.0<4.5.
The engine's exit framework anchors to a tactical sell band near $40.44, with structural invalidation at $37.66. The asymmetric R:R against a reversal hypothesis is 4.53 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates OMCL — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Analyst upside: 32%
Bear case
- ▸Negative momentum